MicroRNA Market - Strategic Insights and Forecasts (2026-2031)

The MicroRNA market is forecast to grow at a CAGR of 15.4%, reaching USD 4.3 billion in 2031 from USD 2.1 billion in 2026.

The Asia Pacific region is experiencing the fastest growth in the microRNA market due to rapid technological progress in the biotech sector, a rising level of healthcare expenditures, and a greater use of precision medicine techniques.

• In 2025, products were the major segment by type, accounting for % share by value, followed by the services segment, contributing to % share in the same year.

• Among microprofiling methods, RNA sequencing is the fastest-growing microRNA profiling method due to its high accuracy, scalability, and ability to provide comprehensive microRNA profiling.

• Cancer is becoming the fastest-growing market segment owing to the rising application of microRNA in early detection, prognosis, and development of targeted oncology therapies.

• By end-user, biotechnology & pharmaceutical companies constitute the fastest-growing segment that is largely driven by increasing investments in RNA-based therapeutics and biomarker research.

Market Dynamics

Drivers

Rising Prevalence of Chronic Diseases

Globally, the increasing prevalence of chronic diseases remains one of the main factors driving the microRNA market. This is mainly because of the growing incidence of cancers, cardiovascular diseases, neurological disorders, and diabetes that are linked with aging populations, sedentary lifestyles, and environmental factors. The escalating health burden has paved the way for the demand for more precise and early-stage diagnostics as well as efficient therapies targeting specific molecules, which are the roles of microRNAs.

• For example, in oncology, particular microRNA signatures are used to pinpoint tumor types and assist doctors in developing personalized treatment plans.

• It was projected that 2,041,910 new cancer cases would be diagnosed in 2025, while 618,120 people would die from the disease in the United States.

• Additionally, in the case of cardiovascular and neurological disorders, microRNAs serve as tools that help to gain a deeper insight into the complex nature of the diseases.

• There are approximately 1.2 million people in Japan suffering from heart failure (HF). The number of patients with HF is growing alongside the aging population of Japan, and it is projected that the figure will be more than 1.3 million by 2030.

• According to the report HF Stats 2025, Heart Failure Epidemiology and Outcomes Statistics, it is estimated that about 6.7 million Americans over 20 years old are living with heart failure (HF), and this number will most likely increase to 8.7 million by 2030.

Market Segmentation

By Application: Cancer

Application-wise, the microRNA market is segmented into cancer, infectious diseases, immunological disorders, cardiovascular disease, neurological disease, and others. The ongoing global burden of such chronic diseases has positively impacted microRNA demand for early detection.

Ongoing investment in R&D operations to expand personalized diagnostics to support the development of tailored therapies as per individual molecular profiles has improved the overall market scope. The development of miRNA mimics and delivery systems, followed by a growing shift towards precision medicine, has accelerated the miRNA-based diagnostics in cardiovascular and oncology.

Improved next-generation sequencing, PCR, and microarrays have made miRNA profiling much faster, thereby further driving development in miRNA-based diagnostics and therapeutics for major chronic diseases. Regulatory fast-track incentives followed by public & private funding are supporting miRNA initiatives, particularly for oligonucleotide therapeutics.

• Ongoing R&D funding targeting specific cancer types has improved market development. For instance, V-Foundation-backed funding to develop “FM-FolamiR-34a,” a modified microRNA to improve triple-negative breast cancer treatment.

• Constant efforts to overcome limitations of current cancer therapies and targeted drugs, such as HER2 Inhibitors, further drive microRNA-based therapeutics demand.

• Introduction of new innovations such as “Cantel”, which features a microRNA-based blood test for breast cancer screening, followed by research studies conducted to explore engineered & encapsulated microRNA deliveries like “Quatsomes”, has provided new growth prospects.

• With global new cancer prevalence estimated to reach from 20 million in 2022 to 35 million in 2050 as per research studies conducted by the WHO and International Agency for Research on Cancer (IARC), the market is set to witness a positive shift to microRNA-based diagnostics to limit such high prevalence.

• Uncovering of new microRNA drugs to treat cancers like glioblastoma (GBM), followed by ongoing pre-clinical research supporting the same, has further unravelled new market opportunities.

Regional Analysis

North America: the US

• USA is witnessing technological advancements in genomics & nucleic acid analysis, followed by research investment in “microRNA 10-b” by companies like TransCode Therapeutics Inc. to treat glioblastoma multiforme (GBM).

• Establishment of microRNA research program by prestigious organizations, namely Foundation of Angelman Syndrome Therapeutics (FAST), showcased a framework for “one-on-one” microRNA therapy in the country for treating Angelman syndrome.

• Regulatory support from the FDA has further positively impacted the frequency of microRNA pre-clinical research studies in the USA.

• With chronic disease prevalence gaining traction, the demand for early detection has increased in the United States. According to the American Association for Cancer Research (AACR), in 2025, the estimated number of new cancer cases reached 2,041,910, with breast, prostate, lung, colorectal, and melanoma cases accounting for the largest share.

• The ongoing research investment to explore microRNA adoption for detecting other chronic conditions, such as endometriosis, further paves the way for regional market expansion.

List of Companies

• Merck KGaA

• Thermo Fisher Scientific Inc.

• QIAGEN N.V.

• Illumina, Inc.

• Takara Bio Inc.

• Agilent Technologies, Inc.

• Horizon Discovery Group plc

• GeneCopoeia Inc.

• OriGene Technologies, Inc.

• Norgen Biotek Corp. 

• Quantabio

• Miltenyi Biotec

• Pattern Computer, Inc.

Merck KGaA is a German-based multinational science and technology company and is one of the world's oldest pharmaceutical and chemical firms. The company operates three major business segments, which include Healthcare, Life Science, and Electronics, while maintaining its operations across more than 60 global markets. Its Healthcare division focuses on therapeutic areas such as oncology, neurology, immunology, and endocrinology, while the Life Science segment provides tools, reagents, and services for research, biotechnology, and pharmaceutical manufacturing.

The Life Science division of Merck KGaA, which operates as MilliporeSigma, has established a major position in the microRNA market. The company provides a comprehensive selection of miRNA research tools, which include qPCR-based detection kits, primers, and reagents that researchers use for gene expression analysis and biomarker discovery. The mirPremier microRNA Isolation Kit functions as a primary product that researchers use to isolate specific miRNA targets for accurate measurement through advanced detection methods. Merck KGaA supports miRNA research and translational medicine through its end-to-end solutions, which begin with sample preparation and end with detection systems that researchers use in academic and industrial research settings.

MicroRNA Market Scope